CIMETIDINE DOES NOT ALTER SPARFLOXACIN PHARMACOKINETICS

被引:0
|
作者
GRIES, JM
HONORATO, J
TABURET, AM
ALVAREZ, MP
SADABA, B
AZANZA, JR
SINGLAS, E
机构
[1] UNIV NAVARRA,E-31080 PAMPLONA,SPAIN
[2] HOP NECKER ENFANTS MALAD,F-75015 PARIS,FRANCE
关键词
SPARFLOXACIN; CIMETIDINE; PHARMACOKINETICS; DRUG INTERACTION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interaction between cimetidine and sparfloxacin was studied in 10 healthy volunteers who received a single oral dose of 400 mg sparfloxacin on the third day of an 8 day cimetidine (400 mg t.i.d.) or placebo randomly assigned treatment. No statistically significant differences were observed in the pharmacokinetic parameters (C-max - AUC - T-1/2 - urinary excretion and metabolic ratio) of sparfloxacin following the 2 treatment. Cimetidine does not affect absorption, metabolism or urinary excretion of sparfloxacin; consequently, patients exposed to this drug combination are not at risk.
引用
收藏
页码:585 / 587
页数:3
相关论文
共 50 条
  • [21] RANITIDINE DOES NOT ALTER ADINAZOLAM PHARMACOKINETICS OR PHARMACODYNAMICS
    SUTTLE, AB
    SONGER, SS
    DUKES, GE
    HAK, LJ
    KORUDA, M
    FLEISHAKER, JC
    BROUWER, KLR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 178 - 178
  • [22] Pharmacokinetics of sparfloxacin in broiler chicken
    Sriranjani, D.
    Kalaiselvi, L.
    Ramesh, S.
    Mathuram, L. N.
    Sriram, P.
    BRITISH POULTRY SCIENCE, 2006, 47 (06) : 720 - 725
  • [23] Effects of food on the pharmacokinetics of sparfloxacin
    Johnson, RD
    Dorr, MB
    Hunt, TL
    Jensen, BK
    Talbot, GH
    CLINICAL THERAPEUTICS, 1999, 21 (06) : 982 - 991
  • [24] DOES CIMETIDINE ALTER THE PROGNOSIS AFTER PERFORATED DUODENAL-ULCER
    SIMPSON, CJ
    LAMONT, G
    MCDONALD, I
    SMITH, IS
    GUT, 1985, 26 (10) : 1118 - 1118
  • [25] DOES CIMETIDINE ALTER THE PROGNOSIS FOLLOWING PERFORATED DUODENAL-ULCER
    LAMONT, G
    SIMPSON, CJ
    MCDONALD, I
    SMITH, IS
    SCOTTISH MEDICAL JOURNAL, 1986, 31 (03) : 198 - 198
  • [26] THE PHARMACOKINETICS OF CIMETIDINE
    KATRUKHA, SP
    KARPENKO, EV
    DAVYDOV, SM
    BLINKOV, IL
    KUKES, VG
    FARMAKOLOGIYA I TOKSIKOLOGIYA, 1986, 49 (05): : 36 - 40
  • [27] Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone
    Trapnell, CB
    Donahue, SR
    Collins, JM
    Flockhart, DA
    Thacker, D
    Abernethy, DR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) : 597 - 602
  • [28] CIGARETTE-SMOKING DOES NOT ALTER TRIAZOLAM PHARMACOKINETICS
    BURSTEIN, ES
    OCHS, HR
    GREENBLATT, DJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (07): : 556 - 556
  • [29] Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate
    Zix, JA
    GeerdesFenge, HF
    Rau, M
    Vockler, J
    Borner, K
    Koeppe, P
    Lode, H
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) : 1668 - 1672
  • [30] Pharmacokinetics of sparfloxacin in patients with renal impairment
    Dorr, MB
    Johnson, RD
    Jensen, B
    Magner, D
    Marbury, T
    Talbo, GH
    CLINICAL THERAPEUTICS, 1999, 21 (07) : 1202 - 1215